A Comperehensive Drug Repurposing Study for Covid19 Treatment: Novel Putative DHODH Inhibitors Show Association to Serotonin-Dopamine Receptors

03 August 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.


Here we discuss the potential of targeting Dihydroorotate dehydrogenase enzyme to help treat Covid 19. Next, we present a very large scale of docking analysis using 7900 drug candidates and 20 Dihydroorotate dehydrogenase structures. Our findings not only identify 28-FDA approved candidate molecules, but also show common characteristics among the candidates, especially their association with serotonin-dopamine receptors. In continuation, we discuss the existing clinical trials for Covid 19 treatment of some of the drug candidates we have identified, supporting that the rest are good candidates.


DHODH inhibition
Dihydroorotate Dehydrogenase Inhibitors
Target prediction
Molecular docking analysis

Supplementary materials

SUPPL-DHODH inhibition for Covid19


Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.